1H-Pyrazole-3-Amide Composition for Psoriasis Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new and effective drugs with new mechanisms of action for treating inflammatory skin diseases such as psoriasis and contact dermatitis, as existing treatments like antibody therapies are temporary and ineffective for severe cases.
Innovation Solution
A pharmaceutical and health functional food composition containing a 1H-pyrazole-3-amide compound derivative is developed, which effectively reduces TNF-α, IL-1β, IL-17A, and Ki67 in mouse models of psoriasis and contact dermatitis, thereby suppressing the diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody treatments that block the IL-23-IL-17 pathway are used, then effectiveness in treating psoriasis is improved, but the treatment effectiveness is temporary and weak in patients with high severity
Solution Approach 1:
The patent changes the molecular target parameter from the IL-23-IL-17 pathway to the TNF-α pathway. By developing small molecule compounds that inhibit TNF-α production and activity, the treatment addresses a different parameter in the inflammatory cascade, potentially providing more sustained and potent effects for severe cases compared to antibody therapies targeting downstream cytokines.
Solution Approach 2:
The patent introduces small molecule compounds as intermediary substances that block TNF-α signaling. These compounds act as mediators between the immune system and the inflammatory response, providing an alternative mechanism to antibody therapies by using small molecules rather than large protein-based antibodies, which may offer different pharmacokinetic properties including longer duration of action.
2Object-affected harmful factors
If existing antibody therapies are used for severe psoriasis, then some inflammatory effects are reduced, but the treatment is ineffective for high severity patients
Solution Approach 1:
The patent changes the therapeutic parameter from blocking downstream IL-23 and IL-17 cytokines to inhibiting upstream TNF-α production. This parameter change in the therapeutic pathway targets the root cause of inflammation more directly, potentially providing reliable effectiveness for severe cases by preventing the cascade before it amplifies.
Solution Approach 2:
The patent employs preliminary action by blocking TNF-α production at an early stage in the inflammatory cascade. By preventing TNF-α synthesis and signaling before it triggers downstream IL-23 and IL-17 production, the treatment addresses inflammation proactively rather than reactively, providing more reliable control in severe cases.
3Adaptability or versatility
If new mechanisms of action are developed, then treatment options for inflammatory skin diseases are expanded, but the complexity of drug development increases
Solution Approach 1:
The patent substitutes the mechanical/biological complexity of antibody-based therapies with small molecule compounds. Small molecules have simpler pharmacokinetic profiles, easier manufacturing processes, and lower costs compared to biologic antibodies, thereby expanding treatment options while reducing development and production complexity.
Solution Approach 2:
The patent employs small molecule compounds that are chemically synthesized rather than biologically manufactured. This approach uses simpler, more stable molecules with longer shelf lives and easier storage requirements compared to antibody therapies, reducing overall system complexity in terms of storage, handling, and distribution infrastructure.
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
The present invention relates to a composition for preventing or treating inflammatory skin diseases, containing a 1H-pyrazole-3-amide compound derivative. Found to reduce TNF-α, IL-1β, IL-17A, and Ki67 in the skin of mouse models of psoriasis or contact dermatitis, the composition can prevent or treat such inflammatory skin diseases by effectively inhibiting psoriasis or contact dermatitis.